ISRCTN ISRCTN23560818
DOI https://doi.org/10.1186/ISRCTN23560818
ClinicalTrials.gov number NCT01635361
Secondary identifying numbers 12494
Submission date
05/07/2012
Registration date
05/07/2012
Last edited
27/10/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr Matthew Boyd
Scientific

School of Pharmacy
University Park
Nottingham
NG7 2RD
United Kingdom

Phone +44 (0)115 9515061
Email matthew.boyd@nottingham.ac.uk

Study information

Study designRandomised interventional trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeQuality of life
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleUnderstanding and appraising the New Medicine Service in the NHS in England
Study objectivesAbout 25% medicines prescribed for longterm conditions are not taken as directed, and approximately 15% people receiving a new medicine take few, if any, doses. The New Medicines Service (NMS) is a community pharmacy service that started in England in October 2011 which involves the pharmacist providing additional support to patients starting a new medicine for some breathing problems (asthma & chronic obstructive pulmonary disease [COPD]), high blood pressure, adult onset diabetes or medicines which reduce blood clotting. It aims to improve the way patients take their medicines improving outcomes and reducing costs to the NHS.
Ethics approval(s)First MREC, 02/05/2012 ref: 12/WM/0096
Health condition(s) or problem(s) studiedAll diseases
InterventionThe effectiveness and cost effectiveness of the NMS will be assessed using a research study where some people will receive the NMS, and some won’t, in order to look at the effect of the NMS on problems with their medicines, medicines taking and use of the NHS in general. Data will be collected in the East Midlands, South Yorkshire and London areas. 500 patients will be recruited from a range of different pharmacies and follow them up at 6, 10 and 26 weeks after starting their new medicine to assess effects on medicines taking behaviour, patients’ reported problems with medicines, referrals to their GP and use of NHS resources. The data gathered will be compared with that being collected routinely by all pharmacies in England to provide wider estimates of cost-effectiveness.

The study will also explore how the NMS service is being implemented by pharmacies. A sample of patients from the main study will be followed in more detail. This will involve recording the consultations with the pharmacist and also interviewing patients about their experience of the service. The patients GPs will be interviewed to investigate their views of the service. The trialists will also try to understand why people decline the invitation for the NMS.

Follow Up Length: 6 months.
Intervention typeOther
Primary outcome measureMedicines adherence measured at 6, 10 and 26 weeks
Secondary outcome measures1. Cost effectiveness measured at 6 months
2. Operation of the NMS measured 1 year from first recruited patient
3. Patients’ understanding of their medicines measured at 10 weeks
4. Pharmacovigilance measured 1 year from first recruited patient
5. Professional relationships measured 1 year from first recruited patient
6. Stakeholder experience measured 1 year from first recruited patient
Overall study start date16/07/2012
Completion date28/02/2014

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsUK Sample Size: 500; Description: The study requires 200 patients in each arm. The sample is calculated to allow for an attrition rate of 20%
Key inclusion criteria1. They are community dwelling patients eligible for NMS (i.e. aged from 14 years starting a new medicine for asthma/COPD, diabetes (Type 2), antiplatelets/anticoagulants or hypertension).
2. There is no upper age limit for providing the NMS hence there is no upper limit for patients taking part in the trial
3. They are able to understand patient/participant study documents
4. They are able and willing to provide informed assent/consent
5. The pharmacist will provide the patient with details of the study to in order to allow the patient to make an informed decision to take part into the study or not
6. Male and female participants
Key exclusion criteria1. Younger patients who may not be able to understand the NMS service and/ or consenting procedure
2. Patients collecting a repeat prescription for a medicine for asthma/COPD, type 2 diabetes mellitus (T2DM), antiplatelets/anticoagulants or hypertension
3. Patients collecting a medicine where the only change from the previous medicine involves a dosage or formulation change only
4. Participants who are unable to understand patient/participant study documents
5. Participants who are unable and unwilling to provide assent/consent
Date of first enrolment16/07/2012
Date of final enrolment28/02/2014

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Nottingham
Nottingham
NG7 2RD
United Kingdom

Sponsor information

University of Nottingham (UK)
University/education

School of Pharmacy
University Park
Nottingham
NG7 2RD
England
United Kingdom

Website http://www.nottingham.ac.uk/
ROR logo "ROR" https://ror.org/01ee9ar58

Funders

Funder type

Government

National Institute for Health Research (NIHR) - Central Commissioning Facility (UK)
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 01/12/2013 Yes No
Results article 10-week follow-up 01/10/2016 Yes No
Results article cost effectiveness results 01/12/2017 Yes No
Results article 26-week follow-up 15/11/2019 27/10/2022 Yes No

Editorial Notes

27/10/2022: Publication reference added.
09/08/2017: Publication reference added.
10/04/2013: The overall trial end date was changed from 31/03/2013 to 28/02/2014